A simple blood draw can help clinicians
to guide therapy decisions.

Comprehensive Genomic Profiling with a simple blood draw with an easy to interpret report.

Blood Sample

2x 10 ml tubes of blood

7 days

Comprehensive genomic
profiling results in
only 7 days

Take action

Clinically relevant
alterations
in 70+ cancer related genes.

The right treatment can make
all the difference.

For patients with advanced solid tumour cancers.

  • Before 1st Line Treatment

    Get ahead of the challenges of tissue testing in
    advanced cancer by utilizing Guardant360® to guide
    1st line treatment decisions.

  • At Progression

    Get genomic information on over 70+ genes, including MSI
    across multiple solid tumors to help inform cancer therapies and
    clinical trials.

A molecular diagnosis can change everything
in an instant.

Published data

Prospective study of 323 NSCLC patients found
Guardant360® improved alteration detection

were unable to get complete
genomic results from tissue biopsy
had targetable alterations detected
by Guardant360® and tissue testing
(n=82) versus tissue testing
alone (n=47)
treated based on Guardant360® had a response or stable disease

Did you know?

Guardant Health offers the Guardant Health Portal app for healthcare professionals to track, access and download Guardant Health reports.

  • Easily search, sort, and review reports
  • On-call support for healthcare
    professionals and patients

Subscribe to our Newsletter

to stay up to date with information from Guardant Health.

Consistently High
Concordance with Tissue

for targetable alterations before 1st NSCLC
therapy

Consistently High
Concordance with Tissue

  • Best-in-class detection
  • Extensively peer reviewed and published
  • Published analytical and clinical validation (refs)
  • Over 150 peer reviewed publications, more than 50 of which include associated clinical outcomes

Tissue has limitations beyond your control!

  • Treatment delays
    Results can be unpredictable, may take a month or longer, and can be incomplete
  • Insufficient availability of tissue
    Exhausted by diagnostic needs and PD-L1 testing
  • Patient burden
    Repeated tissue biopsies expose patients to potential adverse events
  • Practice/staff burden
    Significant coordination involving multiple care team members

Relying solely on tissue can lead to undergenotyping

~ 1 in 2 NSCLC patients are unable to get
guideline-recommended genes for NSCLC2-6

EGFR
ALK
ROSI
BRAF
MET
RET
ERBB2 (HER2)
NTRK

We are here to help
and answer any question you might have.

Contact us

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.